.jpg "Joel E. Gallant, MD, MPH photo")
Executive Director, HIV Medical Affairs
Gilead Sciences Inc.
Joel Gallant is Executive Director of HIV Medical Affairs at Gilead Sciences, where he focuses primarily on HIV therapy. He was previously Medical Director of Specialty Services at Southwest CARE Center in Santa Fe, New Mexico. Prior to joining Gilead in 2017, he held appointments as a Clinical Professor of Medicine at the University of New Mexico School of Medicine and Adjunct Professor of Medicine in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine in Baltimore, where he had been on the faculty for 21 years and was the Associate Director of the Johns Hopkins AIDS Service. He has conducted clinical trials on the treatment of HIV infection and viral hepatitis and has been an investigator in the HIV Prevention Trials Network (HPTN), the Multicenter AIDS Cohort (MACS), and the AIDS Clinical Trials Group (ACTG). Within the HPTN and ACTG he has been involved in international clinical trials, especially in Chiang Mai, Thailand.
Dr. Gallant received his M.D. at the University of California, San Francisco. He completed a residency and chief residency in internal medicine at Yale-New Haven Hospital. He received his M.P.H. at the Johns Hopkins University School of Hygiene and Public Health, and completed a fellowship in infectious diseases at the Johns Hopkins University School of Medicine. He is a fellow in the IDSA and the American College of Physicians. He has served as Chair of HIVMA and was HIVMA representative on the Board of the IDSA. He has served on the Board of Directors of the IAS-USA and the ID Specialty Board of the ABIM. He was a member of the antiretroviral therapy guidelines panels of both the DHHS and the IAS-USA and also served on the IDSA/HIVMA Panel for Primary Care Guidelines for the Management of Persons Infected with HIV.
Dr. Gallant is the recipient of the 2006 HIV Clinical Educator Award from the IDSA/HIVMA. He has written and spoken extensively on HIV infection and antiretroviral therapy. Before joining Gilead, he was the author of 100 Questions and Answers about HIV and AIDS, a book for lay readers, and was editor-in-chief of the Johns Hopkins HIV Guide, a web-based educational tool.
Disclosure: Gilead Sciences (Individual(s) Involved: Self): Employee, Shareholder
Tuesday, October 20, 2020
11:00am – 1:00pm EDT
